Beta 3-adrenoceptors in dog adipose tissue: studies on their involvement in the lipomobilizing effect of catecholamines

J Pharmacol Exp Ther. 1993 Jul;266(1):358-66.

Abstract

The existence of beta 3-adrenoceptors in adipose tissue and their involvement in the control of lipolysis was investigated in dog. Selective beta 3-adrenergic agonists (BRL 37344, SR 58611A and CGP 12177) and catecholamines (isoproterenol and norepinephrine) activated lipolysis in isolated adipocytes (order of potency: isoproterenol > BRL 37344 > norepinephrine > CGP 12177 > SR 58611A). The lipolytic effect of 0.05 microM BRL 37344 was antagonized by the nonselective beta-AR antagonists, but the selective beta 1-(CGP 20712A) and beta 2-(ICI 118551) antagonists were ineffective. Infused to conscious dogs, beta 3-adrenergic agonists increased plasma nonesterified fatty acids levels with an order of potency equivalent to that defined in lipolysis. The lipomobilizing effect induced by the administration of an alpha 2-antagonist (0.01 mg/kg RX 821002 i.v.) was suppressed by bupranolol (0.5 mg/kg) or the combination of CGP 20712A and ICI 118551 (0.25 mg/kg each). The effect of 0.05 mg/kg RX 821002 was only partially suppressed by the same beta-antagonist combination, whereas bupranolol totally abolished it. At 0.5 mg/kg, the RX 821002 effect was not modified by beta-antagonists. The lipomobilization due to infusion of catecholamines (0.1, 0.5 or 5 micrograms/kg/min norepinephrine or 5 micrograms/kg/min epinephrine) was always suppressed by bupranolol or the combination of selective beta-antagonists. Thus dog adipocytes express functional beta 3-ARs. Their stimulation induces lipid mobilization. The lipomobilization of exogenously administered catecholamines is due only to the recruitment of beta 1- or beta 2-ARs. However, endogenous catecholamines released after sympathetic nervous system activation could stimulate beta 3-ARs in adipocytes only if a high level of sympathetic nervous system activity is realized.

Publication types

  • Comparative Study

MeSH terms

  • Adipose Tissue / drug effects
  • Adipose Tissue / metabolism*
  • Adipose Tissue / ultrastructure*
  • Adrenergic beta-Agonists / pharmacology
  • Adrenergic beta-Antagonists / pharmacology
  • Animals
  • Blood Glucose / metabolism
  • Bupranolol / pharmacology
  • Dogs
  • Epinephrine / blood
  • Epinephrine / pharmacology*
  • Epinephrine / physiology
  • Fatty Acids, Nonesterified / blood
  • Insulin / blood
  • Lipid Metabolism*
  • Lipolysis / drug effects*
  • Lipolysis / physiology
  • Male
  • Norepinephrine / blood
  • Norepinephrine / pharmacology*
  • Norepinephrine / physiology
  • Propanolamines / pharmacology
  • Receptors, Adrenergic, beta / physiology*

Substances

  • Adrenergic beta-Agonists
  • Adrenergic beta-Antagonists
  • Blood Glucose
  • Fatty Acids, Nonesterified
  • Insulin
  • Propanolamines
  • Receptors, Adrenergic, beta
  • Bupranolol
  • CGP 12177
  • Norepinephrine
  • Epinephrine